Peptides for perimenopause: what the science actually supports

What did @makeupbygingerb actually say?

Honestly? Not much that can be fact-checked. The transcript is garbled nonsense, a string of syllables that reads like a lip-sync gone wrong or a corrupted audio capture. There are no medical claims in the spoken words themselves. What we do have is the caption, which promotes Valhalla Vitality and claims their peptides "support perimenopause health." That caption is doing all the heavy lifting here, and it is where the actual scrutiny belongs.

The video is essentially an advertisement wearing a wellness hashtag. No dosing information, no specific peptides named, no mechanism explained. Just a brand plug attached to a health condition that affects roughly 1.3 million women annually in the U.S. alone. That context matters when evaluating what viewers are actually being sold.

Does the science back this up?

The claim that peptides broadly "support perimenopause health" is too vague to confirm or refute, which is part of the problem. Some specific peptides have legitimate research behind them. Most do not have randomized controlled trials in perimenopausal women specifically.

GHK-Cu, a copper-binding tripeptide, has shown anti-inflammatory and tissue-remodeling properties in cell and animal studies (Pickart and Margolina, 2018, Biomedicines), and is frequently cited in skin aging discussions relevant to perimenopausal women. BPC-157 has demonstrated gut and musculoskeletal repair effects in rodent models (Sikiric et al., 2018, Current Neuropharmacology), but human trials are largely absent. Ipamorelin and CJC-1295 stimulate growth hormone release, and declining GH is a real feature of aging, but using these peptides to address perimenopausal symptoms has no direct human trial support. The leap from "this peptide does something" to "this peptide supports perimenopause" is not supported by current evidence.

What did they get wrong (or right)?

The creator did not make specific false medical claims in speech, so there is nothing technically incorrect in the transcript. Credit for that, even if it was accidental. But the caption's implication that an unspecified peptide product from one vendor covers perimenopausal health is misleading by omission.

Perimenopause involves estrogen and progesterone fluctuation, vasomotor symptoms, sleep disruption, mood changes, and bone density shifts. No peptide currently has FDA approval to address any of these. The evidence-based interventions for perimenopause include hormone therapy, SSRIs for vasomotor symptoms, and lifestyle modifications (The Menopause Society, formerly NAMS, 2022 position statement). Framing a peptide supplement as something that "supports" this transition without specifying how or which compound implies efficacy the evidence does not support. That is misleading, even if it is not an outright lie.

What should you actually know?

If you are in perimenopause and considering peptide therapy, you deserve actual information, not a TikTok caption and a brand name. Some peptides are being studied for inflammation, skin aging, and metabolic function, all of which are relevant to the perimenopausal transition. But "being studied" is not the same as "proven to work" in your specific situation.

Telehealth platforms that prescribe peptides legally do so through licensed clinicians who assess your individual labs, symptoms, and history. Buying from a vendor because a makeup creator tagged them in a caption is not that. Ask your provider which specific peptide they are recommending, why that one, and what the human evidence looks like. If they cannot answer that, that is a problem. The Federal Trade Commission has also flagged influencer posts promoting health products without disclosing paid partnerships. It is worth noting this video has no #ad or #sponsored tag.

• GHK-Cu has peer-reviewed data on skin and anti-inflammatory effects, but not on hot flashes or hormonal regulation.
• BPC-157 and TB-500 have animal model data only for most indications.
• Ipamorelin and CJC-1295 affect growth hormone axes, not estrogen or progesterone directly.
• No peptide in the category described has FDA approval for any perimenopausal symptom.